LEXINGTON, Mass. & EDINBURGH, U.K.—Quanterix Corp. and DestiNA Genomics Ltd. announced in July that PLOS ONE has published their study detailing a single-probe method for detecting microRNA biomarkers associated with liver toxicity.
The study, entitled “Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury,” is a proof-of-concept paper showing how the scientists combined Quanterix’s Single Molecule Array Detection technology, or Simoa, and DestiNA’s SMART Nucleobase probe chemistry to develop a test for drug-induced liver toxicity that is at once more accurate and swifter than methods commonly employed today. The study was published jointly by Quanterix, DestiNA Genomics, Edinburgh University and the Pfizer-Universidad de Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENyO).
Drug-induced liver injury (DILI) is caused by prescription and over-the-counter medications or herbal and dietary supplements, and may affect as many as 44,000 people in the United States annually, according to the National Institutes of Health, accounting for 10 percent of all cases of acute hepatitis and over 50 percent of the 2,000 cases of acute liver failure in the United States each year. Those numbers are expected to increase as the use of herbal and dietary supplements rises.
Read the rest of the article at ddn-news.com